Purpose or Objective:
To investigate the need for the implementation and development of immobilization and localization devices and other improvements in safety measures in addition to those currently in use in current HDR treatment protocols involving gynecological applicators.
Material and Methods: 55 treatment plans from 27 cervical cancer patients treated with three to 5 intra-cavity cylinder insertions were used. We performed a retrospective study of a dosimetric evaluation due to a possible minor displacement of the cylinder after scanning to the treatment delivery time. The 55 plans that were dosimetrically analyzed post treatment involved treatments for 27 different patients. 22 patients had a hysterectomy with bilateral salpingooophorectomy . In 16 of these twenty two patients the procedure had an abdominal hysterectomy bilateral salpingooophorectomy).Three of the patients had hysterectomies only. The vaginal cylinder applicators which were placed within the patients by a radiation oncologist for administering the treatments included the Capri, Miami, and multi-lumen catheres applicator.
Results:
For the 55 patients whose point dose data were gathered, dose variation at the hottest spot due to a simulated 1mm displacement in the superior inferior direction calculated by normalizing to the average of the endpoints was found to have a minimum value of 0.02% and a maximum value of 12.66% with an average value of 1.43% and a standard deviation of 2.02%. Dose variation at the hottest spot due to a simulated 1mm displacement in the medial lateral direction calculated by normalizing to the average of the endpoints was found to have a minimum value of 12.32% and a maximum value of 22.71% with an average value of 16.96% and a standard deviation of 2.76%. The measurement of dose variation due to a displacement of one degree of rotation along the central axis of the applicator was found to have a minimum value of 0.00% and a maximum value of 2.76% with an average value of 0.63% and a standard deviation of 0.62%.The standard deviation and the mean nearly coincide. The measurement of dose variation due to a displacement of five degrees of rotation along the central axis of the applicator was found to have a minimum value of 0.06% and a maximum value of 13.71% with an average value of 2.15% and a standard deviation of 3.00%.
Conclusion:
The point dose variation due to hypothetical 1 mm medial lateral displacement of a vaginal cylinder applicator make a difference in terms of Grade 1 rectal toxicity as defined by Common Terminology Criteria for Adverse Events v 4.0 in some patients receiving HDR VCBT alone or shortly after EBRT. The point dose variation due to hypothetical 1 mm medial lateral displacement of a vaginal cylinder applicator according to this analysis did reach a crudely obtained cutoff value for RTOG grade greater than or equal to 2 late rectal morbidity for any of the patients receiving HDR VCBT alone or shortly after EBRT. Purpose or Objective: In some cervical cancer patients with extensive parametrial involvement, not all of the tumor can be sufficiently covered with MRI-based image guided brachytherapy using a standard intracavitary/interstitial applicator. An approach with individually designed applicator with oblique needles offers a possibility of better tumor dose coverage in these patients.In this study we tested the feasibility of the 3D printing for the individualized brachytherapy applicator add-on.
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Material and Methods:
A patient in this case report study had extensive parametrial involvement to the pelvic wall. In order to improve the tumor dose coverage we decided to use additional oblique needles for the second application. A preplan for the second application was created based on the dosimetry information from the first application. The information on the optimal location of the oblique needles in the preplan was used to design an individualized interstitial template cap for the ring applicator, which was manufactured with a 3D printing technique. The whole procedure of the cap design and manufacture was performed in 5 days.
Results:
The HR-CTV coverage at the time of the first application ( Figure 1a ) was suboptimal (D90=69%, D100=35%, V100=77%).
________________________________________________________________________________
The volume of the HR-CTV not covered with the prescribed isodose was 19.8 ccm. Oblique needles applied at the time of the second application contributed significantly to a better dose coverage of HR-CTV (D90= 109%, D100= 55%, V100= 93%). The part of the volume not sufficiently covered with the prescribed dose in the first application was boosted using only oblique needles at the end of the second treatment until the dose restrictions for the OAR were reached (Figure 1b) . DVH parameters for HR-CTV of the second application were improved accordingly: D90= 119%, D100= 61%, V100= 96%. The volume of the HR-CTV not covered with the prescribed isodose was reduced to 2.4 ccm. The position on the ring, oblique angle and the insertion depth of the oblique needles in the second application were measured on the MR images and compared with the pre-plan. The average differences were relatively small (position on the ring: 10°, oblique angle: 8°, insertion depth: 4 mm).
Conclusion: Individualized approach to cervical cancer patients with extensive parametrial involvement at the time of brachytherapy can contribute significantly to an improved dose coverage of the HR-CTV. An individualized 3D printed interstitial cap for the ring applicator with oblique needles is an efficient option for these patients. Median age of the series was 62 years. Total hysterectomy, double anexectomy, pelvic lymphadenectomy and peritoneal washing was made in 61,4 %. The majority of the pathologycal FIGO stages were IB (77,2 %). Exclusive brachytherapy was performed using vaginal cylinders with 3 cm of diameter (50,9 %). The reference isodosis covering the proximal 3 cm of the vagina (96,4 %). The dose was specified at 5 mm distant from the surface of the cylinder. Dose schedule with high dose rate brachytherapy was 21 Gy in 3 fractions. The median of dose equivalent received in the rectum was 31,8 Gy and in bladder 38 Gy.
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Results: At the moment of this analysis there are 4 relapses: 2 of them live with disease, and 2 death for tumor; 110 cases live without disease (94,82 %), and 2 cases death for another cause. With median follow-up of 26 months, free disease survival was 90.2% and 2 years overall survival was 88.3%. No toxicity was reported in the 52,6%, and when it was present the most frequent was cystitis (12.3%).
